Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04391894
Recruitment Status : Recruiting
First Posted : May 18, 2020
Last Update Posted : May 10, 2021
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

The purpose of Part 1 of the study is to determine the safety and efficacy of topical ocular ECF843 compared to topical ocular vehicle for the relief of the signs and symptoms associated with moderate to severe dry eye disease (DED).

Part 2 of the study is exploratory only and intended to explore potential areas of differentiation between ECF843 and Xiidra® (lifitegrast 5% ophthalmic solution) for the treatment of subjects with dry eye disease.


Condition or disease Intervention/treatment Phase
Dry Eye Drug: ECF843 0.45 mg/mL Drug: ECF843 0.15 mg/mL Other: ECF843 vehicle Drug: ECF843 mg/mL Drug: Xiidra® Phase 2

Detailed Description:

The study will be conducted in 2 parts: Part 1 - efficacy and safety of ECF843 vs vehicle, followed by Part 2 - exploratory assessment of ECF843 vs Xiidra®.

Part 1 uses a double-masked design where subjects will be randomized to receive BID or TID treatment with either ECF843 or vehicle for 56 days.

Part 2 will be initiated only if safety and efficacy of ECF843 during Part 1 is demonstrated. Part 2 uses an open-label design of ECF843 versus Xiidra® for 84 days after a 2-week vehicle run-in phase.

Approximately 800 subjects will need to be screened in Part 1 to have approximately 680 subjects randomized into the 56-day treatment period.

For Part 2, it is estimated that up to 200 subjects will need to be screened to randomize up to 160 subjects into the 2 treatment arms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 680 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double-masked
Primary Purpose: Treatment
Official Title: A Randomized, Double-masked, Multicenter Study to Evaluate the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
Actual Study Start Date : October 6, 2020
Estimated Primary Completion Date : May 13, 2021
Estimated Study Completion Date : March 21, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Diseases
Drug Information available for: Lifitegrast

Arm Intervention/treatment
Experimental: ECF843 0.45 mg/mL TID or vehicle (Part 1)
Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
Drug: ECF843 0.45 mg/mL
Topical ocular eye drop administered 3 times per day (TID)

Experimental: ECF843 0.15 mg/mL TID or vehicle (Part 1)
Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
Drug: ECF843 0.15 mg/mL
Topical ocular eye drop 2 or 3 times/day (BID orTID)

Placebo Comparator: ECF843 vehicle TID (Part 1)
Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
Other: ECF843 vehicle
Topical ocular eye drop 2 or 3 times/day (BID orTID)

Experimental: ECF843 0.15 mg/mL BID or vehicle (Part 1)
Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
Drug: ECF843 0.15 mg/mL
Topical ocular eye drop 2 or 3 times/day (BID orTID)

Placebo Comparator: ECF843 vehicle BID (Part 1)
Randomized to a 1:1:1:1:1 ratio in Part 1. Topical ocular eye drops.
Other: ECF843 vehicle
Topical ocular eye drop 2 or 3 times/day (BID orTID)

Experimental: ECF843 -Part 2 (concentration/frequency TBD from Part 1)
Randomized in a 1:1 ratio in Part 2. Topical ocular eye drops. Exploratory Arm only.
Drug: ECF843 mg/mL
Topical ocular eye drop (concentration and dosing frequency to be determined from Part 1).

Active Comparator: Xiidra® -Part 2 (5% lifitegrast BID)
Randomized in a 1:1 ratio in Part 2. Topical ocular eye drops. Exploratory Arm only.
Drug: Xiidra®
Topical ocular eye drop administered twice per day (BID)
Other Name: 5% lifitegrast




Primary Outcome Measures :
  1. Part 1: Change from baseline in Symptom Assessment in Dry Eye (SANDE) score [ Time Frame: 56 Days (baseline to End of Part 1) ]
    The primary aim of the study is to demonstrate improvement in moderate to severe DED with ECF843. This will be evaluated by measuring signs and symptoms as primary estimands. The analysis of the primary estimands will be based on Full Analysis Set (FAS) 1. The two primary estimands are the change from baseline in SANDE symptom score and the change from baseline in composite corneal fluorescein staining score in Part 1.

  2. Part 1: Change from baseline in composite corneal fluorescein staining score [ Time Frame: 56 Days (baseline to End of Part 1) ]
    The primary aim of the study is to demonstrate improvement in moderate to severe DED with ECF843. This will be evaluated by measuring signs and symptoms as primary estimands. The analysis of the primary estimands will be based on Full Analysis Set (FAS) 1. The two primary estimands are the change from baseline in SANDE symptom score and the change from baseline in composite corneal fluorescein staining score in Part 1.


Secondary Outcome Measures :
  1. Part 1: Change from baseline in inferior and central corneal fluorescein staining [ Time Frame: 56 Days (baseline to End of Part 1) ]
    To evaluate the improvement of ECF843 vs vehicle in corneal damage by quadrant

  2. Part 1: Incidence and severity of ocular and non-ocular adverse events [ Time Frame: 56 Days ]
    To evaluate the safety of ECF843 vs Vehicle



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent must be obtained before any assessment
  • Adult male or female subjects 18 years of age or older
  • At least 6 months history of dry eye disease in both eyes
  • Must use, or feel the need to use, artificial tears/gels/lubricants on a regular basis
  • Composite corneal fluorescein staining score ≥ 4 (modified National Eye Institute (NEI) scale) in at least one eye
  • Schirmer score ≥ 1 and ≤ 10 mm after 5 minutes in at least one eye
  • Patients with Sjögren's Syndrome

Exclusion Criteria:

  • Ocular infection in either eye within 30 days prior to Screening
  • Use of artificial tears, gels, lubricants within 4 hours of the Screening Visit
  • Use of contact lenses in either eye within 14 days of Screening
  • Uncontrolled ocular rosacea
  • Clinically significant conjunctivochalasis in either eye
  • Corneal conditions
  • Severe ocular conditions such as herpes, graft versus host disease, Stephen's Johnson Syndrome, sarcoidosis
  • Currently active, or history of ocular allergies during the time of year the patient will be participating in the study
  • Patients with current punctal plugs or punctal cauterization or occlusion
  • Chronic medications (both over the counter and prescription) that have not been stable for at least 30 days prior to Screening.
  • Use of Restasis®, Cequa®, or Xiidra® within 30 days prior to Screening
  • Use of ocular, nasal, inhaled, or systemic corticosteroids within 30 days of Screening
  • History of malignancy of any organs system
  • Pregnant or nursing women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04391894


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals

Locations
Show Show 58 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04391894    
Other Study ID Numbers: CECF843A2201
First Posted: May 18, 2020    Key Record Dates
Last Update Posted: May 10, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Dry Eye
Sjogrens
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eye Diseases
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Lifitegrast
Ophthalmic Solutions
Pharmaceutical Solutions